Human Liver Stem Cell Vesicles for Cellular Senescence Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing extracellular vesicles derived from mesenchymal stem cells are not as effective in reducing cellular senescence as those derived from human liver stem cells, and there is a need for a more effective method to address age-related diseases and conditions associated with cellular senescence.
Innovation Solution
A method of manufacturing pharmaceutical preparations of extracellular vesicles from human liver stem cells, specifically isolating and purifying them from a non-oval human liver pluripotent progenitor cell line, and testing their senescence-reducing activity using a SA-β-galactosidase-based assay to select effective preparations.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If extracellular vesicles are derived from mesenchymal stem cells, then the manufacturing process is well-established, but the senescence-reducing efficacy is insufficient
Solution Approach 1:
The patent changes the source cell type parameter from mesenchymal stem cells to human liver stem cells, which fundamentally alters the properties of the derived extracellular vesicles. This parameter change results in vesicles with enhanced senescence-reducing efficacy while maintaining a feasible manufacturing process using standard cell culture and vesicle isolation techniques.
2Reliability
If extracellular vesicles are derived from older donors or cultured for extended periods, then the availability of cell material increases, but the expected senescence-reducing activity should decrease
Solution Approach 1:
The human liver stem cells possess inherent self-renewal capabilities that allow them to maintain their functional properties during extended culture periods. This self-service mechanism enables the cells to continue producing high-quality extracellular vesicles with potent senescence-reducing activity, effectively overcoming the typical age-related decline in cellular function.
Solution Approach 2:
The patent establishes a validated methodology for characterizing and quality-controlling extracellular vesicles derived from human liver stem cells. This preliminary action includes defining specific markers and activity thresholds that ensure consistent senescence-reducing efficacy, allowing the process to reliably produce therapeutic-grade vesicles regardless of culture duration or donor age.
3Manufacturing precision
If a non-oval human liver pluripotent progenitor cell line is used, then the specificity and potency of extracellular vesicles are enhanced, but the manufacturing process becomes more specialized
Solution Approach 1:
The patent applies local quality by selecting a specific human liver pluripotent progenitor cell line with defined characteristics (non-oval morphology, specific marker expression profile). This localized selection ensures that the extracellular vesicles produced have the precise properties needed for high-potency senescence-reducing therapy, with the cell line expressing markers such as EpCAM, CD13, CD24, and HNF4A while being negative for markers like CD45 and CD34.
Data Source
Figure 1A~1B
Figure 2A~2B
Figure 3
AI summary
There is disclosed a preparation of extracellular vesicles derived from human liver stem cells, preferably from a non-oval human progenitor cell line that expresses hepatic cell markers, which is capable of reducing the senescence of a population of senescent cells, as measured in a SA-ß-galactosidase-based cellular senescence assay. Also disclosed are therapeutic applications of the preparation of extracellular vesicles derived from human liver stem cells according to the invention. Therapeutic applications include the reduction of cellular senescence, e.g. in an vitro or ex vivo method, as well as the therapeutic treatment of diseases and conditions known to be related to ageing and cellular senescence, such as for example atherosclerosis, diabetes mellitus type 2, asthenia, and others.